These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11522122)

  • 1. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.
    Layton D; Pearce GL; Shakir SA
    Drug Saf; 2001; 24(9):703-13. PubMed ID: 11522122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinations with tolterodine.
    Williams SG; Staudenmeier J
    Psychiatr Serv; 2004 Nov; 55(11):1318-9. PubMed ID: 15534031
    [No Abstract]   [Full Text] [Related]  

  • 4. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
    Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
    Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experiences with tolterodine.
    Nilvebrant L
    Life Sci; 2001 Apr; 68(22-23):2549-56. PubMed ID: 11392625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D; Jarvis B
    Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder.
    Raes A; Hoebeke P; Segaert I; Van Laecke E; Dehoorne J; Vande Walle J
    Eur Urol; 2004 Feb; 45(2):240-4. PubMed ID: 14734013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine: a clinical review.
    Crandall C
    J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
    Harvey MA; Baker K; Wells GA
    Am J Obstet Gynecol; 2001 Jul; 185(1):56-61. PubMed ID: 11483904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolterodine once-daily in treatment of the overactive bladder.
    Peters KM; Huang RR
    Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.
    Armstrong RB; Luber KM; Peters KM
    Int Urol Nephrol; 2005; 37(2):247-52. PubMed ID: 16142551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.